RELATED STUDY
An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse.
Key Findings: Botanical drug substance (BDS) CBD, given after the inflammatory insult, attenuates injury and motility in intestinal models of inflammation. These findings sustain the rationale of combining CBD with other minor Cannabis constituents and support the clinical development of BDS CBD for IBD treatment.
Type of Study: Animal Study
Study Result: Positive
Study Location(s): Italy, Spain
Year of Pub: 2016
Cannabinoids Studied: Cannabichromene (CBC), Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
Chemotype: Chemotype III
Sub-Ratio: ~1:11 (THC:CBD)
Dosage: The composition (%, w/w) of the main phytocannabinoids in CBD BDS was CBD 63.9 ± 5.9, Δ9-THC 3.0. cannabigerol 2.8, cannabichromene 3.1, cannabidivarin 1.4. A standardized C. sativa extract with high content in CBD (botanical drug substance, 63.9% w/w of CBD content) or pure CBD. In the experimental model of colitis pure CBD, CBD BDS or vehicle were given intraperitoneally (5–30 mg/kg) or by oral gavage (10–60 mg/kg) for three consecutive days. In the experimental model of upper gastrointestinal transit pure CBD, CBD BDS, or vehicle were given intraperitoneally (1–10 mg/kg) or by oral gavage (5–60 mg/kg) 30 min (intraperitoneally) or 1 h (oral gavage) before the administration of the marker, to both control mice, and mice with increased intestinal motility induced by the inflammatory agent croton oil.
Route of Administration: Injection, Oral (Ingestion)
Link to study
